A scientist works in a laboratory at the Novavax facility in Gaithersburg, Maryland (Jon Cherry/Bloomberg via Getty Images)

No­vavax tem­pers its rev­enue ex­pec­ta­tions as it un­veils PhI­II da­ta for bi­va­lent boost­er

As No­vavax re­ports third quar­ter re­sults, the vac­cine mak­er is tem­per­ing its ex­pec­ta­tions once again on Covid-19 sales.

The com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.